EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are considered to be effective treatments for advanced non-small cell lung cancer (NSCLC) patients with sensitizing EGFR mutations, including exon 19 deletion and exon 21 L858R mutations. However, with the development of EGFR mu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncol Lett
Main Authors: YANG, YANG, ZHANG, BIAO, LI, RUTIAN, LIU, BAORUI, WANG, LIFENG
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2016
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4841118/
https://ncbi.nlm.nih.gov/pubmed/27123149
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2016.4409
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados